Table 2.
Representative CRISPR/Cas-based engineering strategies in probiotic and beneficial microorganisms: functional outcomes, application relevance, and experimental validation context.
| Microorganism/Strain | CRISPR/Cas strategy | Genetic target/modification | Main outcome | Relevance to probiotic/validation context | Ref. |
|---|---|---|---|---|---|
| Lactobacillus crispatus NCK1350 | Endogenous type I-E CRISPR-Cas | Targeted deletions, nucleotide substitution and chromosomal insertion, including p-gtf editing | 643-bp p-gtf deletion reached 100% efficiency; stop-codon insertion, single-nucleotide substitution, prophage-region deletion and gfp integration were also achieved | Established an endogenous editing platform for functional genomics and engineering of a beneficial/probiotic-associated species/without demonstrated food-related performance | Hidalgo-Cantabrana et al. (2019) |
| Limosilactobacillus reuteri ATCC PTA 6475 | CRISPR-Cas9-assisted ssDNA recombineering | Sequence-specific chromosomal edits at multiple loci | CRISPR counterselection increased recovery of desired edits to 90–100% for three tested targets and enabled codon-level mutagenesis | High-efficiency genome-engineering platform for a probiotic LAB/ no food-matrix assessment | Oh and van Pijkeren (2014) |
| Limosilactobacillus reuteri 03 | Endogenous type II-A CRISPR-Cas9 | Gene deletion, point mutation, large-fragment deletion and gene integration | Editing efficiencies reached 95.46% for deletion and 86.36% for point mutation; a 40-kb deletion and 1,743-bp integration (73.9%) were demonstrated | Advanced endogenous editing platform for development of a probiotic chassis and live biotherapeutic products/ without demonstrated functional efficacy | Guo et al. (2023) |
| Lacticaseibacillus casei LC2W | CRISPR-Cas9D10A nickase (pLCNICK) | In-frame deletion of four genes and chromosomal eGFP insertion | Targeted deletions and insertions were achieved with efficiencies of 25–62% in a one-step workflow | Rapid and precise genome engineering in a health-promoting and food-associated LAB/ no technological phenotype or food-matrix validation | Song et al. (2017) |
| Lactiplantibacillus plantarum AR113 | CRISPR-Cas9 | Single and multiple knoc-kout of bsh genes | bsh genes differentially affected growth in bile-containing media, aggregation, surface properties and adhesion to HT-29 cells; bsh2 was linked to adhesion | Functional identification of genetic determinants relevant to gastrointestinal fitness and colonization/ no evidence of improved probiotic efficacy | Wu et al. (2022) |
| Lactiplantibacillus plantarum AR113 | CRISPR-Cas9 | Deletion of mucin/adhesion-associated genes, including Lp_1431, Lp_2233 and Lp_2792; chromosomal RFP labeling | Triple deletion reduced adhesion to HT-29 cells from 175 to 114 bacteria/100 cells and shortened intestinal persistence in mice from 14 to 11 days; acid and bile tolerance were largely unchanged | Functional dissection of determinants of adhesion and intestinal persistence/ not food-process validation | Qin et al. (2022) |
| Lactiplantibacillus plantarum WCFS1 and SPC 72-1; Levilactobacillus brevis SPC-SNU 70–2 | Cas9-gRNA ribonucleoprotein (RNP) + RecE/T | 50-bp deletion and stop-codon introduction in hlyIII | ΔhlyIII mutants were obtained in all three strains; free hemoglobin levels decreased by 27.0%, 74.3 and 5.0%, respectively, although the functional role of hlyIII requires further validation | Demonstrates transient RNP-based Cas9 delivery that reduces reliance on plasmid-borne CRISPR components; the functional role of hlyIII and its relevance to strain safety require further validation | Kim et al. (2025) |
| Lactiplantibacillus plantarum WCFS1 | Inducible two-plasmid CRISPR-Cas9 knock-in system | Chromosomal insertion of mCherry reporter and SARS-CoV-2 receptor-binding domain expression cassettes (~0.8–1.3 kb) | Stable chromosomal insertion enabled inducible or constitutive expression of heterologous proteins in the cytoplasm or on the cell surface | Demonstrates the capacity of L. plantarum to serve as a genetically stable delivery chassis for functional heterologous proteins/ not food-related validation | Wiull et al. (2025) |
| Clostridium butyricum | Heterologous type II CRISPR-Cas9 and endogenous type I-B CRISPR-Cas | Targeted deletion of spo0A and aldh | The endogenous type I-B system enabled seamless deletion with efficiencies up to 100%; heterologous Cas9 imposed a strong transformation burden | Expanded the genetic toolbox for a probiotic anaerobe and highlighted advantages of endogenous systems/ technological performance not assessed | Zhou et al. (2021) |
| Clostridium butyricum | CRISPR-Cas12a | Scarless genome manipulation, anaerobic reporter system, plasmid curing and acetaldehyde-pathway engineering | Markerless editing was established; aldh overexpression increased enzyme activity by 79.29% as a proof of concept | Advanced platform for functional and metabolic engineering under strict anaerobic conditions/ no food-matrix validation | Li D. et al. (2026) |
| Bifidobacterium animalis subsp. lactis | Endogenous type I-G CRISPR-Cas and CRISPR cytosine base editor | 500-bp deletion and nonsense mutation of tetW; additional genomic edits | tetW deletion abolished tetracycline resistance; C-to-T base editing restored tetracycline susceptibility in multiple strains | Direct example of removing an undesirable antimicrobial-resistance phenotype from probiotic bifidobacteria/ food-use safety requires separate evaluation | Pan et al. (2022) |
| Bifidobacterium animalis AR668 | CRISPR-Cas9 | Knockout of genes 0348 and 0208; homology-arm optimisation and inducible plasmid curing | Successful targeted knockouts and establishment of an inducible plasmid-curing system | Provides a platform for functional-genetic analysis and rational modification of bifidobacteria/without food-process validation | Li et al. (2023) |
| Bifidobacterium longum, B. adolescentis, B. pseudocatenulatum and related strains | CRISPR-Cas9 cytosine base editor (cBEST) | DSB-free C-to-T base editing; disruption of conserved metabolic targets | Restriction-modification bypass markedly improved editing efficiency, and the same editing design was portable across several Bifidobacterium species | Expands precision editing for probiotic bifidobacteria while avoiding double-strand breaks/ no direct food-related functional performance demonstrated | Lin et al. (2025) |
| Bifidobacterium breve and other bifidobacterial species | CRISPRi using nuclease-dead Cas9 orthologs | Targeted repression of reporter genes and endogenous genes involved in nucleotide and carbohydrate metabolism | A one-plasmid CRISPRi platform achieved efficient gene repression across multiple bifidobacterial species without extensive strain-specific optimisation | Portable functional-genomics platform for commercially important and health-associated bifidobacteria/functional-genomics tool rather than a food-application study | Friess et al. (2025) |
| Bifidobacterium animalis subsp. lactis (six commercial strains) | Endogenous type I-G CRISPR-Cas | Knockout of glycoside hydrolases within the Balac_1593–Balac_1601 cluster | Editing was validated across six commercial strains; Balac_1601 deletion abolished melibiose and raffinose utilization, and sequential editing was demonstrated | Enables genotype–phenotype mapping and future strain improvement directly in commercial probiotic strains; no food-matrix performance assessment | Raftopoulou et al. (2026) |
| Lacticaseibacillus rhamnosus GG (LGG) | Endogenous type II-A CRISPR-Cas | Targeted deletions and insertions; chromosomal gusA integration | Editing efficiencies of 11.1–25.0% were obtained, and a stable GUS-positive LGG reporter strain was generated for tracking in complex communities | Enables investigation of probiotic persistence and provides a platform for functional strain construction/ no demonstrated improvement in probiotic efficacy | Xie et al. (2026) |
| Levilactobacillus brevis EG040 | CRISPR/Cas9 genome editing | gadR overexpression; norG deletion | gadR overexpression increased GABA secretion by 37.9% and survival in simulated gastric solution by 19%; norG deletion reduced GABA secretion by 97.3% and impaired growth | Engineering of a food-derived GABA-producing LAB; links GABA biosynthesis with a probiotic-relevant stress-resistance phenotype/no direct validation in a food matrix reported | Jo et al. (2026) |
| Escherichia coli Nissle 1917 (EcN) | Engineered type I-E CRISPR-Cas3 | CRISPR targeting of mcr-1, blaNDM-1 and tet(X) | Engineered EcN efficiently blocked acquisition of targeted ARGs in vitro and showed immunity to their transfer in the zebrafish intestine | CRISPR itself provides a defined protective function to a probiotic chassis/ no food-system validation | Fang et al. (2024) |
| Escherichia coli Nissle 1917 (EcN) | Prime editing (Cas9 nickase + reverse transcriptase + pegRNA) | Precise substitutions, insertions and deletions; genomic barcoding; ARG-free chassis construction | Prime editing enabled precise genome modification and construction of a barcoded, antibiotic-resistance-gene-free probiotic platform | Extends probiotic engineering to programmable precision editing with a limited genomic footprint/probiotic efficacy and food-related performance not evaluated | Chen et al. (2025) |
| Escherichia coli Nissle 1917 (EcN) | Compact BLCas9 from a type II-C system of Bifidobacterium longum | Dual-plasmid genome editing and targeted metabolic engineering | Robust/multiplex editing was established, and extracellular GABA production was enhanced | Designer-probiotic example combining a probiotic chassis with an engineered bioactive metabolic function/food-matrix performance and health effects not established | Liu et al. (2026) |
| Lactococcus lactis NZ9000 | Inducible CRISPRi (dCas9) | Single/multiple gene repression; identification of LLNZ_07335 as a bile salt hydrolase | CRISPRi repressed gene expression by up to 99%; it identified a functional determinant of bile salt resistance | Links functional genomics with a probiotic-relevant stress-tolerance trait in an important food-grade LAB/no food-process validation | Xiong et al. (2020) |
| Lactococcus lactis NZ9000 | Chromosomal and plasmid-based inducible CRISPRi | Conditional silencing of acmA and the essential gene ybeY | Chromosomal dCas9 integration reduced expression ~20-fold relative to plasmid expression, minimized leakage and enabled tightly controlled silencing of essential genes | Tunable functional-genomics platform for food-grade and beneficial L. lactis/not demonstrated food-related performance | Huang et al. (2025) |
| Lactococcus lactis NZ9000 | CRISPR-Cas9 knock-in +Cre/loxP genome reduction | Chromosomal integration of a high-activity uricase variant and genome streamlining | The engineered strain reached 2.34 U/mL uricase activity and completely degraded ~500 μM urate within 20 h; moderate colonization was observed in mice | Functional food-grade probiotic chassis with a defined therapeutic metabolic activity; relevant to designer probiotics/live biotherapeutics/ not a validated food application | Tang et al. (2026) |
The validation context describes the experimental setting reported for each study; using a food-associated microorganism does not, by itself, demonstrate performance in food production or food matrices. ARG, antimicrobial-resistance gene; Cas, CRISPR-associated protein; CRISPR, clustered regularly interspaced short palindromic repeats; dCas9, nuclease-deficient Cas9; DSB, double-strand break; EcN, Escherichia coli Nissle 1917; GABA, γ-aminobutyric acid; GH, glycoside hydrolase; GUS, β-glucuronidase; LGG, Lacticaseibacillus rhamnosus GG; pegRNA, prime-editing guide RNA; RBD, receptor-binding domain; RNP, ribonucleoprotein.